Incannex Healthcare joins AASM Foundation Corporate Recognition Program; IHL-42X advances toward potential oral treatment for obstructive sleep apnea

Reuters03-25
<a href="https://laohu8.com/S/IHLXF">Incannex Healthcare</a> joins AASM Foundation Corporate Recognition Program; IHL-42X advances toward potential oral treatment for obstructive sleep apnea
  • Incannex Healthcare entered a partnership agreement with the AASM Foundation, joining its Corporate Recognition Program as it advances IHL-42X toward a potential oral treatment for obstructive sleep apnea.
  • IHL-42X is positioned as a potential first-in-class therapy, targeting a large undertreated market where many patients cannot tolerate or adhere to existing options.
  • The program’s regulatory profile strengthened after IHL-42X received FDA Fast Track designation, supporting a potentially expedited development pathway.
  • Clinical momentum continues with advancement into the DReAMzz study, a Phase 2 crossover dose-optimisation trial intended to support a pivotal Phase 3 program.
  • As part of the partnership, the company will sponsor an AASM Foundation Focused Projects Grant for Junior Investigators to be awarded in 2026, broadening its visibility within the sleep medicine research community.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-033842), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment